Biomarker ID | 1002 |
PMID | 23059047 |
Year | 2012 |
Biomarker | ABL2+SEMA4D+ITGAL+C1QA+TIMP1+CDKN1A |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Blood |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: Testing: (2·3, 95% CI 1·39–3·70) |
Effect on Pathways | NA |
Experiment | low-risk group Vs high-risk group |
Type of Biomarker | Prognostic |
Cohort | Patients with castration-resistant prostate cancer (n=62) were used as a training set, and 140 patients with castration-resistant prostate cancer in a validation set |
Senstivity | NA |
Specificity | NA |
AUC | Training: 0·90 [95% CI 0·78–0·96] |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | quantitative PCR |
Clinical | NA |
Remarks | low-risk group with a median survival of more than 34·9 months (median survival was not reached) and a high-risk group with a median survival of 7·8 months; Low risk: 2×ABL2+SEMA4D+ITGAL –C1QA–TIMP1–CDKN1A<21.21; High Risk: 2×ABL2+SEMA4D+ITGAL –C1QA–TIMP1–CDKN1A>21.21 |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | ABL2, SEMA4D, ITGAL, C1QA, TIMP1, CDKN1A |